Displaying 41 - 50 of 84 for Cancer - All
  • Mesothelioma Study (H-36952)
    • This study combines immunotherapy and surgery for the treatment of mesothelioma.
  • METRIC Study (H-34400)
    • Patients with "Triple Negative Breast Cancer" that are gpNMB over-expressing are invited to participate in a new drug study to see if CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients with this diagnosis.
  • MOHEL Study (H-8701)
    • Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant.
  • Multiple Myeloma Study (H-33837
    • The purpose of this study is to explore a drug combination alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
  • NanoPac Therapy for Mucinous Pancreatic Cyst (H-41791)
    • This is a national study looking at how safe and effective NanoPac therapy is for patients with a mucinous pancreatic cyst .
  • NanoPac Therapy for Pancreatic Cancer (H-41433)
    • This is a national study looking at how safe and effective NanoPac therapy for patients with pancreatic cancer.
  • Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer (H-36359)
    • This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
  • NexTSTEPS Study (H-39002)
    • The purpose of this study is to evaluate a program that we have developed for advanced cancer patients and their family caregivers.
  • PALLAS Study (H-39113)
    • The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • PALLET Study (H-36507)
    • This study will look at effects the combination of palbociclib and letrozole may have on estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer tumors which have not yet been treated.